Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease in the world. The rising prevalence of nonalcoholic steatohepatitis (NASH) has led to a 170% increase in NASH cirrhosis as the listing indication for liver transplantation from 2004 to 2013. As of 2018, NASH has overtaken hepatitis C as an indication for liver transplantation in the USA. After liver transplantation, the allograft often develops recurrent NAFLD among patients with known NASH cirrhosis. In addition to recurrent disease, de novo NAFLD has been reported in patients with other indications for liver transplantation. In this review, we will discuss the risk factors associated with recurrent and de novo NAFLD, natural course of the disease, and management strategies after liver transplantation.

Original languageEnglish (US)
Pages (from-to)428-435
Number of pages8
JournalJournal of Clinical and Translational Hepatology
Issue number3
StatePublished - 2021


  • De novo NAFLD
  • De novo NASH
  • Nonalcoholic fatty liver disease
  • Nonalcoholic steatohepatitis
  • Posttransplant
  • Recurrent NAFLD
  • Recurrent NASH

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Nonalcoholic fatty liver disease after liver transplant'. Together they form a unique fingerprint.

Cite this